Varalakshmi, "Protective effects of
certoparin sodium, a low molecular weight heparin derivative, in experimental atherosclerosis," Clinica Chimica Acta, vol.
Tebbe et al., "A randomized, double-blind study of
certoparin vs.
(3.) Diener HC, Ringelstein EB, von Kummer R, et al Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin
certoparin: results of the PROTECT Trial.
All patients received initial therapy of subcutaneous LMWH, such as dalteparin,
certoparin (Sandoparin[R]), or enoxaparin.
LMWH preparations evaluated were
certoparin, dalteparin, enoxaparin, nadroparin, reviparin, and tinzaparin.